CANAGLIFLOZIN

Product information

English Name：Canagliflozin

English Alias： (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol；(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol

中文名称：坎格列净

中文别名： 坎格列嗪；(1S)-1,5-脱氢-1-C-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-D-葡萄糖醇

CAS号：842133-18-0

Formula：C24H25FO5S

Molecular weight：444.516

Appearance：White solid.

Purity：99.0%

Use&Pharmacology

Canagliflozin (canagliflozin) is an SGLT2 inhibitor drug, which can reduce blood sugar by breaking down glucose and excreting it through the kidneys. In addition to good blood sugar control, canagliflozin (canagliflozin) ) Canagliflozin's most eye-catching effect is weight loss and few hypoglycemic events, which has broad prospects.

Canagliflozin (Canagliflozin) is an oral diabetes drug that is taken once a day. It belongs to a new class of selective sodium glucose co-transporter 2 (SGLT2) inhibitors. Absorb and increase the excretion of blood sugar in the urine to lower the body's blood sugar level. Compared with non-diabetic people, the kidneys of people with type 2 diabetes can reabsorb a large amount of glucose into the blood, which may push up blood sugar levels.

Canagliflozin is the first SGLT2 inhibitor approved by the FDA for the treatment of type II diabetes in adult patients. SGLT is a kind of glucose transporter protein. There are two subtypes, namely SGLT1 and SGLT2, which are distributed in the small intestinal mucosa and renal tubules, and can transport glucose into the blood. Canagliflozin can inhibit SLCT2, so that the glucose in the renal tubules cannot be smoothly reabsorbed into the blood and excreted in the urine, thereby reducing the blood glucose concentration. Since glucose is excreted into the urine through the kidneys, it is accompanied by side effects such as renal damage, symptomatic hypotension, and fungal infections. Nine clinical trials involving 10285 patients have proved the safety and effectiveness of Invokana, which can be used alone or in combination with other blood sugar lowering drugs. In a 26-week double-blind controlled trial, 584 type II diabetes patients were divided into three groups, namely 100 mg canagliflozin group, 300 mg canagliflozin group and placebo group. Compared with placebo, 100 mg The canagliflozin group reduced HbA1c by an average of 0.91%, and the 300mg canagliflozin group reduced HbA1c by an average of 1.16%.

Package&Storage

Package：1kg/bag, 10kg/drum, 25kg/drum (on request)

Storage&Validity：Cool, shading, dry and sealed/2years